Lymphoplasmacytic Lymphoma

@JudithTrotman1 @MinnemaMonique @c_thieblemont #KarimaAmaador @lymphomaOz #lymphoma #MZL #WM #WaldenströmsMacroglobulinemia (@WomenInLymphoma)

The CD20-targeted CAR T-cell therapy MB-106 led to responses and was well tolerated in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor. @mshadman @fredhutch @EHA_Hematology #EHA2023 #oncology https://t.co/NEbQErcVsD (@OncLive)

Carlos Fernandez de Larrea (@fdezdelarrea), hematólogo del @hospitalclinic y jefe del grupo sobre Mieloma, amiloidosis, macroglobulinemia y otras gammapatías del @idibaps. Coordinador del ensayo del #MielomaMúltiple. Por ✍ @carmenfefe: ➡️https://t.co/mboz5HJW6M (@diariomedico)

In a single-center phase 1/2 trial, MB-106 produced ongoing responses and a favorable safety profile in patients with Waldenström macroglobulinemia who were refractory to a BTK inhibitor. @mshadman @fredhutch @EHA_Hematology #EHA2023 #oncology https://t.co/ViIyzyXWFW (@OncLive)

My mum had cold agglutinin disease as a complication of Waldenstrom’s Macroglobulinemia. (@pauliec80859931)

Congrats on the interesting study! Im wondering if some of the emzl and nodal mzl patients may have been lpl/wm which are more commonly associated with an m protein. Would explain the lower response to single agent Rituximab (@Charanpreet_14)

Wrapped up our second day of interviews here at #EHA2023 with @mshadman (@fredhutch), who spoke on MB-106 in patients with Waldenström's macroglobulinemia & follicular lymphoma, the SEQUOIA trial & more! Check out our coverage here: 👉 https://t.co/2U3kjqJyaP @EHA_Hematology (@VJHemOnc)

I am #proud to share that our paper on Waldenstrom macroglobulinemia in #latam has been published in #Hematology/Oncology Clinics of North America. Thanks to all the team for the hard work. #LATAM @gelamm_latam @dra_v_hungria @erivaserra @CarlosChiattone 🇨🇴🇧🇷🇺🇾 #lymphoma (@HumbertoMar_Cor)

📣Our latest @TheIACH Webinar: Management of Waldenstrom Macroglobulinemia: an update Now available on-demand! 📽️View the full webinar for FREE ⬇️⬇️⬇️ https://t.co/HHXnQkRGVP @MinnemaMonique @Mohty_EBMT (@TheIACH)

📣Join @MinnemaMonique TODAY for @TheIACH Webinar: Management of Waldenstrom Macroglobulinemia: an update FREE registration👉https://t.co/EoWxOb7MpB @Mohty_EBMT (@TheIACH)

📣Join us NOW! ⬇️ https://t.co/rF7AyMtvBh Management of Waldenstrom Macroglobulinemia: an update FREE registration!✍️ @MinnemaMonique @Mohty_EBMT (@TheIACH)

📣Join @MinnemaMonique TOMORROW for @TheIACH Webinar: Management of Waldenstrom Macroglobulinemia: an update with FREE registration👉 https://t.co/EoWxOb7eA3 @Mohty_EBMT (@TheIACH)

👉🏽💻@MinnemaMonique #WM #WaldenstromMacroglobulinemia update webinar - This WED MAY 24 Free registration 👉🏽 https://t.co/tfNFyCoq2a (@WomenInLymphoma)

Please join me for live Q&A this Wednesday 24th of May after the @TheIACH Webinar: Management of Waldenstrom Macroglobulinemia FREE registration⬇️ https://t.co/QAedxKKfap @Mohty_EBMT (@MinnemaMonique)

📣Join us for this upcoming @TheIACH Webinar: Management of Waldenstrom Macroglobulinemia: an update with @MinnemaMonique FREE registration⬇️ https://t.co/EoWxOb7eA3 @Mohty_EBMT (@TheIACH)

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia | Journal of Clinical Oncology https://t.co/tPDTO24jzv (@syed_abutalibmd)

Good teaching case from @BloodJournal Images in #Hematology that (1) not all M-spikes are myeloma, (2) not all lymphoplasmacytic lymphomas are IgM isotype, and (3) remember to request MYD88 and CXCR4 mutations in this setting. #mmsm https://t.co/OpVazjbeNA (@docbraunstein)

No difference in 4-year PFS between MYD88 mutant vs wild-type with frontline BR (benda/ritux) in Waldenstrom Macroglobulinemia #waldenstroms #wm #hematology #mayoclinic #myd88 @MyelomaDrKapoor (@NateDahlPharmD)

The CD19 #antigen has gotten a lot of attention from FDA-approved #CARTcelltherapies, but Mustang Bio is focused on a CD20-targeted #CARTcelltherapy for #nonHodgkinlymphoma, #chroniclymphocyticleukemia, & #Waldenstrommacroglobulinemia. https://t.co/V7GaF1ZXJv #ASGCT22 #ASGCT2022 (@Slabodkin)

#Myeloma Paper of the Day: CD19-directed chimeric antigen receptor T cell therapy in #Waldenström macroglobulinemia shows both in vitro & in vivo preclinical efficacy and activity in 3 patients, whose remission durations were 3-26 months: patients):https://t.co/Q8eIqzL1Ux. (@Myeloma_Doc)

New #JITC short report: CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience https://t.co/gw0qB7kAtg @LiaPalomba @davidquallsmd @ESmithMDPhD (@jitcancer)

B-cell Lymphoma Flow Cytometry Simplified B-cell = CD19+ CD5+/CD10- = CLL (CD23+) Mantle cell (CD23-) CD10+ = Follicular Burkitt DLBCL (GCB subtype) CD5-/CD10- = Marginal zone Lymphoplasmacytic/Waldenstrom's macroglobulinemia Hairy cell leukemia DLBCL (non-GCB) (@AaronGoodman33)

Our latest study in Waldenström's Macroglobulinemia is out in @ScienceAdvances We found mutated MYD88 in normal B cells. This challenges our understanding of lymphomagenesis (mutated MYD88 ≠ lymphoma) and urges alternative methods of disease monitoring https://t.co/xFxOsZjl31 (@BrunoPaiva_UNAV)

Heme Board Review - Bing Neel Syndrome! Rare manifestation of Waldenström’s macroglobulinemia/LPL Infiltration of the CNS by lymphoplasmacytic cells Usually at disease relapse but can occur at presentation CSF cytology = flow CD5-/CD10- MYD88 L265P+ Rx = HDMTX, ibrutinib (@AaronGoodman33)

Venetoclax in Previously Treated Waldenström Macroglobulinemia ⁦@JCO_ASCO⁩ 👉🏻 ORR84%👉🏻CXCR4 mutations did not affect treatment response or progression-free survival #mmsm | Journal of Clinical Oncology https://t.co/jDzNGbOCPS (@SLentzsch)

Morning Board Review - Bing Neel Syndrome! Rare manifestation of Waldenström’s macroglobulinemia/LPL Infiltration of the CNS by lymphoplasmacytic cells Usually at disease relapse but can occur at presentation CSF cytology = flow CD5-/CD10- MYD88 L265P+ Rx = HDMTX, ibrutinib (@AaronGoodman33)

Waldenstorm macroglobulinemia #mmsm ➡️Lymphoid (+ve B cell markers, CD20)/plasmacytoid (+ve CD138)👇 ➡️Mutations: 🩸MYD88:L265P,most common, helps in diff from MM, mutated=good prog 🩸CXCR4:less common, mutated=worse prog ➡️excellent review @MorieGertz: https://t.co/UmDrQj69wt (@HadidiSamer)

Recently,[Dale. Blood. 2020] showed the CXCR4 inhibitor mavorixafor can increase circulating PMNs and decrease infections in WHIM patients. Interestingly, the same CXCR4 mutation in WHIM is seen in Waldenstrom macroglobulinemia and is associated with worse responses to ibrutinib (@AaronGoodman33)

Anyone know of #CART trials for Waldenstrom Macroglobulinemia ongoing ? (Seen reports of WM to rx DLBCL getting cd19 car) @MediHumdani @DrMiguelPerales @drjgauthier @bhemato @kenderian_ss (@kansagraMD)

Interesting. Would treat as MM. 2019 - Simultaneous Presentation of Waldenström's Macroglobulinemia and MYD88 Gene Mutation with Multiple Myeloma https://t.co/imK0mvoxlB #mmsm #wmsm (@mtmdphd)